Clinical Trial Update: Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 1, Phase 2]

View source ↗

Summary

This update describes a Phase 1/2 clinical trial evaluating a triplet regimen of azacitidine, venetoclax, and gilteritinib in patients with recurrent or refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)
• Xospata (gilteritinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1, Phase 2 | Status: RECRUITING